Cerevel Therapeutics Holdings Inc (CERE) stock has gained 97.73% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives CERE stock a score of 65 out of a possible 100.
That rank is primarily influenced by a short-term technical score of 79. CERE's rank also includes a long-term technical score of 71. The fundamental score for CERE is 46. In addition to the average rating from Wall Street analysts, CERE stock has a mean target price of $46.33. This means analysts expect the stock to rise 36.31% over the next 12 months.
CERE has an Overall Score of 65. Find out what this means to you and get the rest of the rankings on CERE!
Cerevel Therapeutics Holdings Inc (CERE) stock is higher by 8.66% while the S&P 500 has gained 2.2% as of 1:55 PM on Tuesday, Dec 7. CERE has gained $2.71 from the previous closing price of $31.28 on volume of 132,020 shares. Over the past year the S&P 500 has gained 27.10% while CERE has gained 97.73%. CERE lost -$3.10 per share in the over the last 12 months.
Click Here to get the full Stock Report for Cerevel Therapeutics Holdings Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
